MX2021013656A - Formulaciones antibioticas de cannabinoides-terpenos. - Google Patents

Formulaciones antibioticas de cannabinoides-terpenos.

Info

Publication number
MX2021013656A
MX2021013656A MX2021013656A MX2021013656A MX2021013656A MX 2021013656 A MX2021013656 A MX 2021013656A MX 2021013656 A MX2021013656 A MX 2021013656A MX 2021013656 A MX2021013656 A MX 2021013656A MX 2021013656 A MX2021013656 A MX 2021013656A
Authority
MX
Mexico
Prior art keywords
antibiotic
cannabinoids
terpenes
formulations
active ingredients
Prior art date
Application number
MX2021013656A
Other languages
English (en)
Spanish (es)
Inventor
Charles J Thompson
Mark C Pryjma
Dana M Lambert
Manisha Dosanjh
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of MX2021013656A publication Critical patent/MX2021013656A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021013656A 2019-05-06 2020-05-06 Formulaciones antibioticas de cannabinoides-terpenos. MX2021013656A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962843687P 2019-05-06 2019-05-06
PCT/CA2020/050613 WO2020223811A1 (en) 2019-05-06 2020-05-06 Antibiotic cannabinoid-terpene formulations

Publications (1)

Publication Number Publication Date
MX2021013656A true MX2021013656A (es) 2022-01-06

Family

ID=73050953

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013656A MX2021013656A (es) 2019-05-06 2020-05-06 Formulaciones antibioticas de cannabinoides-terpenos.

Country Status (11)

Country Link
US (3) US20220218654A1 (enExample)
EP (1) EP3965794A4 (enExample)
JP (1) JP2022532116A (enExample)
KR (1) KR20220005066A (enExample)
CN (1) CN113710263A (enExample)
AU (1) AU2020270175A1 (enExample)
CA (1) CA3138811A1 (enExample)
IL (1) IL287729A (enExample)
MX (1) MX2021013656A (enExample)
SG (1) SG11202110779SA (enExample)
WO (1) WO2020223811A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013656A (es) * 2019-05-06 2022-01-06 Univ British Columbia Formulaciones antibioticas de cannabinoides-terpenos.
KR102524364B1 (ko) * 2022-10-24 2023-04-24 전북대학교산학협력단 칸나비디올 및 타우린을 포함하는 치주염 예방 또는 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630507B1 (en) 1998-04-21 2003-10-07 The United States Of America As Represented By The Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
US7323576B2 (en) 2004-10-01 2008-01-29 Alphora Research Inc. Synthetic route to dronabinol
WO2012012498A2 (en) 2010-07-20 2012-01-26 Pulmatrix, Inc. Use of trp channel agonists to treat infections
CN107405314A (zh) * 2015-02-27 2017-11-28 埃布公司 包含纯化的大麻素与至少一种类黄酮、萜或矿物质的组合的组合物
AU2016225026A1 (en) * 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
EP3380096A4 (en) * 2015-11-24 2019-10-23 Constance Therapeutics, Inc. CANNABIS OIL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
WO2018011813A1 (en) 2016-07-14 2018-01-18 Therapix Biosciences Ltd. Compositions and methods of potentiating antimicrobials
CA3067542A1 (en) * 2017-06-19 2018-12-27 Syddansk Universitet Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections
WO2019198056A1 (en) * 2018-04-14 2019-10-17 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition for treating conditions and/ or symptoms associated with a stressful event
WO2020000024A1 (en) * 2018-06-28 2020-01-02 Botanix Pharmaceuticals Ltd Antibacterial treatment using cannabinoid combinations
CA3111979A1 (en) * 2018-09-05 2020-03-12 Nemus Bioscience, Inc. Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains
MX2021013656A (es) * 2019-05-06 2022-01-06 Univ British Columbia Formulaciones antibioticas de cannabinoides-terpenos.

Also Published As

Publication number Publication date
SG11202110779SA (en) 2021-10-28
JP2022532116A (ja) 2022-07-13
IL287729A (en) 2021-12-01
EP3965794A4 (en) 2023-01-18
CA3138811A1 (en) 2020-11-12
CN113710263A (zh) 2021-11-26
US20230355573A1 (en) 2023-11-09
KR20220005066A (ko) 2022-01-12
US11744819B2 (en) 2023-09-05
AU2020270175A1 (en) 2021-12-02
WO2020223811A1 (en) 2020-11-12
US20220233494A1 (en) 2022-07-28
US20220218654A1 (en) 2022-07-14
EP3965794A1 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
MX2021006094A (es) Uso de cannabinoides en el tratamiento de epilepsia.
MX2021009646A (es) Uso de cannabinoides en el tratamiento de epilepsia.
MX2026002647A (es) Composiciones y metodos de uso que comprenden sustancias con acciones de plasticidad neural administradas a dosificaciones y formulaciones no psicodelicas / psicotomimeticas
CL2019000510A1 (es) Adenovirus armado con un activador de células t biespecífico (bite).
MX2022001776A (es) Terapias de combinacion de inmuno oncologia con conjugados de il-2.
MX2021013581A (es) Composiciones de nanoemulsiones que comprenden ingredientes biologicamente activos.
MX2021008702A (es) Uso de cannabinoides en el tratamiento de las comorbilidades asociadas a la epilepsia.
CO2021007993A2 (es) Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina
UY31073A1 (es) Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap)
MX2019011219A (es) Administracion rapida y controlada de composiciones con efectos sequito restaurados.
MX2020003250A (es) Composiciones sinegísticas de pesticidas y métodos para la entrega de ingredientes activos.
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
BR112022010754A2 (pt) Análogos de rapamicina e usos dos mesmos
MX2021013656A (es) Formulaciones antibioticas de cannabinoides-terpenos.
DOP2022000235A (es) Inhibidores macrocíclicos de las peptidilarginina deiminasas
CL2004000527A1 (es) Composicion farmaceutica para inyeccion intramuscular que comprende un ester de testosterona, 25 a 45% v/v de aceite de ricino como vehiculo y un cosolvente, formulacion farmaceutica, y uso.
AR119043A1 (es) Métodos para acelerar la cicatrización mediante el uso de composiciones cannabinoides
MX2021013010A (es) Composiciones y metodos para modular la actividad del complemento.
CL2020002199A1 (es) Compuesto de anillo de metillactama y uso farmacéutico del mismo.
CO2022008308A2 (es) Tieniloxazolonas y análogos
MX2023011701A (es) Composicion farmaceutica para liberacion controlada de treprostinil.
CL2025002366A1 (es) Compuesto que contiene trifluorometilsulfonilo.
CR20110445A (es) Vitamina d3 y análogos de la misma para aliviar efectos secundarios asociados con la quimioterapia
CL2024002379A1 (es) Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso
CL2023002840A1 (es) Análogos de rifamicina en combinación con vancomicina y usos de los mismos